Abstract

Zolpidem, a non-benzodiazepine hypnotic, was identified in the blood of 29 subjects arrested for impaired driving. Zolpidem concentrations ranged from 0.05 to 1.4 mg/L (mean 0.29 mg/L, median 0.19 mg/L). In the subjects whose cases we reviewed where zolpidem was present with other drugs and/or alcohol, symptoms reported were generally those of CNS depression. Symptoms included slow movements and reactions, slow and slurred speech, poor coordination, lack of balance, flaccid muscle tone, and horizontal and vertical gaze nystagmus. In five separate cases, where zolpidem was the only drug detected (0.08–1.40 mg/L, mean 0.65 mg/L, median 0.47 mg/L), signs of impairment included slow and slurred speech, slow reflexes, disorientation, lack of balance and co-ordination, and “blacking out.” Although no quantitative relationship between blood concentrations and degree of driving impairment is currently possible, it is reasonable to conclude that because of its specific activity as a sleep inducer, blood concentrations consistent with therapeutic doses of zolpidem have the potential to affect driving in a negative way, and that concentrations above the normal therapeutic range would further impair a person's level of consciousness and driving ability.

References

1.
Meeker
J E
,
Baselt
R C
.
Six cases of impaired driving following recent use of the sleep inducer zolpidem (Ambien®)
. Presented at the
American Academy of Forensic Sciences Annual Meeting
,
Nashville, TN
,
02
1996
.
2.
Logan
B K
,
Case
G C
,
Gordon
A
.
Carisoprodol, meprobamate and driving impairment
.
J Forensic Sci
2000
;
45
(
3
):
619
-
23
.
3.
Goeringer
K
,
Raymon
L
,
Christian
G D
,
Logan
B K
.
Postmortem forensic toxicology of selective serotonin reuptake inhibitors: A review of pharmacology and report of 168 cases
.
J Forensic Sci
2000
;
45
(
3
):
633
-
48
.
4.
Mattila
M J
,
Vanakoski
J
,
Kalska
H
,
Seppälä
T
.
Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory
.
Pharm Biochem Behav
1990
;
59
(
4
):
917
-
23
.
5.
Greenblatt
D J
,
Harmatz
J S
,
von Moltke
L L
,
Ehrenberg
B L
,
Harrel
L
,
Corbett
K
, et al
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo
.
Clin Pharmacol Ther
1998
;
64
:
553
-
61
.
6.
Albin
H
,
Vincon
G
,
Vincon
J
,
Hermann
P
,
Thiercelin
J F
.
Study of the pharmacokinetics of zolpidem in healthy volunteers after repeated administration: effect on antipyrene clearance
. In:
Sauvanet
J P
,
Langer
S Z
,
Morselli
P L
, editors.
Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach
.
New York
,
Raven Press
,
1988
;
369
-
70
.
7.
Salvá
P
,
Costa
J
.
Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications
.
Clin Pharmacokinet
1995
;
29
(
3
):
142
-
53
.
8.
Vandel
S
,
Vandel
B
,
Joanne
C
,
Trocherie
S
,
Bechtel
P
,
Larribaud
J
.
Influence of ethnic origin on the clinical pharmacology of zolpidem
. In:
Sauvanet
J P
,
Langer
S Z
,
Morselli
P L
, editors.
Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach
.
New York
,
Raven Press
,
1988
;
390
-
1
.
9.
Bianchetti
G
,
Dubruc
C
,
Thierclin
J F
,
Bercoff
E
,
Bouchet
J L
,
Emiriau
J P
, et al
Clinical pharmacokinetcs of zolpidem in various physiological and pathological conditions
. In:
Sauvanet
J P
,
Langer
S Z
,
Morselli
P L
, editors.
Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach
.
New York
,
Raven Press
,
1988
;
255
-
63
.
10.
Pichard
L
,
Gillet
G
,
Bonfils
C
,
Domergue
J
,
Thenot
J P
,
Maurel
P
.
Oxidative metbolism of zolpidem by human liver cytochrome P450S
.
Drug Metab Disp
1995
;
23
(
11
):
1253
-
62
.
11.
Singh
B N
Effects of food on clinical pharmacokinetics
.
Clin Pharmacokinet
1999 Sep;
37
(
3
):
213
-
55
.
12.
Levine
B
,
Wu
S C
,
Smialek
J E
.
Zolpidem distribution in postmortem cases
.
J Forensic Sci
1999
;
44
(
2
):
369
-
71
.
13.
Harvengt
C
,
Hulhoven
R
,
Desager
J P
,
Coupez
J M
,
Guillet
Ph
,
Fuscau
E
, et al
Drug interactions investigated with zolpidem
. In:
Sauvanet
J P
,
Langer
S Z
,
Morselli
P L
, editors.
Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach
.
New York
,
Raven Press
,
1988
;
165
-
73
.
14.
Roger
M
,
Dallot
J Y
,
Salmon
O
,
Neveux
E
,
Gitton
J P
,
Gerson
M
, et al
Hypnotic effect of zolpidem in geriatric patients: a dose finding study
. In:
Sauvanet
J P
,
Langer
S Z
,
Morselli
P L
, editors.
Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach
.
New York
,
Raven Press
,
1988
;
279
-
87
.
15.
Rush
C R
.
Behavioral pharmacology of zolpidem relative to benzodiazepines: A review
.
Pharm Biochem Behav
1998
;
61
(
3
):
253
-
9
.
16.
Physicians Desk Reference
. 53rd edition.
Medical Economics Company
,
Montvale, NJ
,
1999
.
17.
Borberly
A A
,
Youmbi-Balderer
G
,
Jaggi-Schwarz
K
.
Zolpidem (10 and 20 mg): Hypnotic action and residual effects after a single bedtime dose
. In:
Sauvanet
J P
,
Langer
S Z
,
Morselli
P L
, editors.
Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach
.
New York
,
Raven Press
,
1988
;
205
-
10
.
18.
Vermeeren
A
,
Danjou
P E
,
O'Hanlon
J F
.
Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance
.
Hum Psychopharm Clin Exp
1998
;
13
(
S2
):
S98
-
S108
.
19.
Tharp
V
,
Burns
M
,
Moscowitz
H
.
Development and field test of psychophysical tests for DWI arrest
. DOT-HS-8-01970,
03
1981
.
This content is only available via PDF.
You do not currently have access to this content.